⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206448 | 0.83 | — | — | |
| SCHEMBL2162473 | 0.81 | — | — | |
| SCHEMBL112619 | 0.80 | — | — | |
| SCHEMBL23928292 | 0.80 | — | — | |
| SCHEMBL23928302 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL26646222 | 0.79 | — | — | |
| SCHEMBL2508488 | 0.78 | HTR2A (0.32) | — | |
| SCHEMBL20512584 | 0.78 | — | — | |
| SCHEMBL2387067 | 0.76 | HTR2A (0.31) | — | |
| SCHEMBL380825 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 647 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137984-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | claimed |
| WO-2024118926-A1 | 4-(3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL)-PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF THE KRAS(G12D) MUTANT ONCOPROTEIN FOR THE TREATMENT OF CANCER | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2024-06-06 | — | — | WO | claimed |
| WO-2024051766-A1 | MOLECULAR GLUE COMPOUND BASED ON CEREBLON PROTEIN DESIGN AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-03-14 | — | — | WO | claimed |
| WO-2024032747-A1 | TRICYCLIC COMPOUNDS AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2024-02-15 | — | — | WO | claimed |
| US-20240043435-A1 | TYK-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2024-02-08 | — | — | US | claimed |
| WO-2023244815-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | claimed |
| WO-2023225244-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | BIOGEN MA INC. (US) | 2023-11-23 | — | — | WO | claimed |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2023-10-19 | — | — | US | claimed |
| US-20230096517-A1 | GLUTARIMIDE SKELETON-BASED COMPOUNDS AND APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2023-03-30 | — | — | US | claimed |
| EP-3802549-B1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2023-03-01 | — | — | EP | claimed |
| EP-2750678-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | claimed |
| EP-2750504-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | claimed |
| WO-2014086807-A1 | NOVEL PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | claimed |
| WO-2014086806-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | claimed |
| WO-2013033240-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | claimed |
| WO-2013033258-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | claimed |
| WO-2013033228-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | claimed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | claimed |
| EP-2217226-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | claimed |
| WO-2009061879-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | claimed |